Serbia’s Torlak Institute on Monday signed a technology transfer agreement with the Russian Direct Investment Fund and the Russian pharmaceuticals company Generium under which the Russian side will transfer to the Serbian side information on procedures and technologies required for production of the Sputnik V COVID-19 vaccine in Serbia.
The news was announced by Serbian Minister for Innovation Nenad Popovic, who also co-chairs a Serbian-Russian cooperation committee.
Popovic noted that sensitive information related to production of the Sputnik V was now available to the Torlak Institute, which he said would produce three validation series of the vaccine in April.
Samples of the series will be sent to Moscow’s Gamaleya Institute for quality control, he said.
If they pass validation, Torlak will start producing the vaccine, which is expected to happen by May 20.
Popovic said Serbia would thus become the first country in Europe to produce the Sputnik V vaccine.
“This is the start of the renewal of our country’s sovereignty when it comes to vaccine production, which will be an important resource for every state in the future,” Popovic said.
Source: tanjug, photo: sputnikvaccine.com